The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy

Title:The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy

Volume: 18 Issue: 28

Author(s): Na Liu, Rongtong Zhao, Yue Ma, Dongyuan Wang, Chen Yan, Dongxian Zhou*, Feng Yin*Zigang Li*

Affiliation:

• Department of Breast Surgery, The Second Affiliated Hospital of Jinan University, Shenzhen People's Hospital, Shenzhen, Guangdong,China

• State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055,China

• State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055,China

Keywords: Epigenetic targets, Inhibitors, Cancer therapy, Drug discovery, DNMT, HDAC.

Abstract: Epigenetics process is the heritable change in gene function that does not involve changes in the DNA sequence. Until now, several types of epigenetic mechanisms have been characterized, including DNA methylation, histone modification (acetylation, methylation, etc.), nucleosome remodeling, and noncoding RNAs. With the biological investigations of these modifiers, some of them are identified as promoters in the process of various diseases, such as cancer, cardiovascular disease and virus infection. Epigenetic changes may serve as potential “first hits” for tumorigenesis. Hence, targeting epigenetic modifiers is being considered as a promising way for disease treatment. To date, six agents in two epigenetic target classes (DNMT and HDAC) have been approved by the US Food and Drug Administration (FDA). Most of these drugs are applied in leukemia, lymphoma therapy, or are combined with other drugs for the treatment of solid tumor. Due to the rapid development of epigenetics and epigenetics targeted drugs, it is becoming an emerging area in targeted drug design.

Cite this article as:

Liu Na , Zhao Rongtong, Ma Yue , Wang Dongyuan , Yan Chen, Zhou Dongxian *, Yin Feng *, Li Zigang *, The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy, Current Topics in Medicinal Chemistry 2018; 18 (28) . https://dx.doi.org/10.2174/1568026618666181115092623